23andMe : La FDA approuve la vente de tests génétiques sans conseil médical, http://www.alliancevita.org/2017/04/23-and-me-la-fda-approuve-la-vente-de-tests- genetiques-sans-conseil-medical, 2017. ,
Outlook to 2022, EvaluatePharma, 2017. ,
Pharmaceutical industry gets high on fat profits ,
The Most Profitable Industries In 2016, https://www.forbes.com/sites/sageworks/2016/08/06/the-most-profitable-industries, 2016. ,
Trends in pharmaceutical mergers and acquisitions, https://biopharmadealmakers.nature.com/users/9880-biopharma- dealmakers/posts/13880-trends-in-pharmaceutical-mergers-and-acquisitions, 2017. ,
Ten year deal activity in pharmaceuticals industry stands at $2.4 trillion, https://www.consultancy.uk/news/13046/ten-year-deal-activity-in-pharmaceuticals-industry- stands-at-24-trillion, 2017. ,
These Were the 10 Biggest Pharmaceutical Deals of 2016, 2016. ,
Inside the $21 Billion War for a Blockbuster Cancer Drug, https://www.bloomberg.com/news/articles/2015-03-05/abbvie-emerges-with-21- billion-deal-in-fight-to-the-very-end, 2017. ,
What it takes to be called 'big pharma, 2017. ,
Roche's near-term biosimilar threat in Europe ,
Who's The Best In Drug Research? 22 Companies Ranked, https://www.forbes.com/sites/matthewherpernew-report-ranks-22-drug- companies-based-on-rd/#567dd38d4268, 2014. ,
Curvilinearity in the diversification-performance linkage: an examination of over three decades of research, Strategic Management Journal, vol.9, issue.2, pp.155-174, 2000. ,
DOI : 10.1002/smj.4250090502
Consequences of corporate refocusing: Ex ante evidence, Academy of Management Journal, pp.398-412, 1992. ,
A longitudinal study of the cause and consequences of changes in diversification in the U.S. pharmaceutical industry, pp.187-199, 1977. ,
The Motley Fool, Big Pharma Diversification: A Winning Model or Recipe for Disaster?, https://www.fool.com/investing/general, 2014. ,
Rebuilding Big Pharma's Business Model, In Vivo, The Business & Medicine report, 2003. ,
Why pharma megamergers work, https://www.mckinsey.com/industries/pharmaceuticals-and-medical-products/ourinsights/why-pharma-megamergers-work, McKinsey & Company report, 2017. ,
Vaccine Market Analysis by type, http://www.grandviewresearch.com/industry-analysis/vaccine-market, consulté en septembre, 2017. ,
Generating value in generics: Finding the next 5 years growth ,
Fight or flight? Diversification vs. Rx-focus in big pharma's quest for sustained growth ,
The Power of focus, http://www.bain.com/publications/articles/the-power-of-focus-in-medical-technology.aspx, 2017. ,
The Boston Consulting Group, Capitalizing on the crisis: New Ways to Create Value in Biopharma ,
The Boston Consulting Group, The Future of Pharma: Adjusting the Pharma R&D Model, 2017. ,
New Ecosystems in Pharma: Maturing markets mean new models are needed, In Vivo: The Business & Medicine report, 2012. ,
Les géants pharmaceutiques absents du Top 10 des labos les plus innovants, http://www.latribune.fr/entreprises-finance/industrie/chimie-pharmacie/les-geants- pharmaceutiques-absents-du-top-10-des-labos-les-plus-innovants-554264, 2017. ,
Top 10 Pharmaceutical Companies 2017, https://igeahub.com, 2017. ,
Working Capital: never been better, What the top performing companies are doing differently ,
Analyse financière en IFRS, Economica, 2011. ,